PPP2R1A

Across TCGA pan-cancer cohorts, PPP2R1A Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PPP2R1A data layer compared with 25 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in sarcoma (SARC), where higher PPP2R1A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PPP2R1A expression acts as an unfavorable survival marker.

SARC, THCA, and LIHC are the cancer types where PPP2R1A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SARC	OS	Median	All	0.164	0.839	<.001	12	view →
THCA	OS	Median	All	0.294	0.945	<.001	6	view →
LIHC	DFS	Median	II,III,IV	0.090	0.429	.016	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

PPP2R1A–SARC (OS)

Open the SARC breakdown →